Breakthrough study stops fat-eating prostate cancer cells

Patients with castration resistant prostate cancer (CRPC) usually have a poor prognosis. In part, this is due to the cancer's ability to resist anti-androgen therapy. A study shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer's sensitivity to the anti-androgen drug enzalutamide.